1. Home
  2. SPRO

as 05-30-2025 12:42pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Founded: 2013 Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 33.0M IPO Year: 2017
Target Price: $5.00 AVG Volume (30 days): 9.5M
Analyst Decision: Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.28 EPS Growth: N/A
52 Week Low/High: $0.51 - $2.48 Next Earning Date: 05-13-2025
Revenue: $44,584,000 Revenue Growth: -59.83%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

SPRO Daily Stock ML Predictions

Share on Social Networks: